Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Nov 26, 2024
Deals
Sarepta broadens pipeline via siRNA deal with Arrowhead, paying $825M up front
CEO Ingram sees “the one significant strategic transaction” to transform Sarepta’s future, while Arrowhead preps for first-ever launch
BioCentury | Sep 14, 2023
Distillery Therapeutics
Inhibition of calprotectin for vascular calcification in chronic kidney disease
BioCentury | Apr 25, 2023
Deals
April 25 Quick Takes: Final outcome for decades-old Spectrum is Assertio merger
Plus: Arrowhead buoyed by pulmonary data and updates from Novartis, Vedanta and Ventoux
BioCentury | Nov 23, 2022
Data Byte
Translational spotlight on East-West innovation
Collaborations between investigators at Asian and Western universities in BioCentury’s Distillery present licensing and partnering opportunities
BioCentury | Sep 1, 2022
Management Tracks
Regulators need better ways to brand what they do
Drawing top talent means agencies must persuade candidates that careers are infused with purpose and support a vital mission
BioCentury | Feb 9, 2022
Discovery & Translation
Translational trendspotting: a Distillery dive into infectious disease
Host targets, cross-reactive mAbs and COVID-19 countermeasures stand out in BioCentury’s Distillery
BioCentury | Jan 29, 2022
Product Development
Jan. 28 Quick Takes: Lilly halts Olumiant in lupus, portends rejection in atopic dermatitis
Plus Regeneron, Sanofi withdraw Libtayo sBLA and updates from TG, Novavax and more
BioCentury | Jan 7, 2022
Distillery Therapeutics
Inhibiting the RAGE-DIAPH1 interaction for Type I and Type II diabetes
BioCentury | Jan 30, 2021
Distillery Therapeutics
Targeting the RAGE-LCP2 interaction for sepsis
DISEASE CATEGORY: Infectious disease
INDICATION: Sepsis Disrupting the interaction between the immunoglobulin-like cell surface receptor RAGE and the adaptor protein LCP2 could treat sepsis.
INDICATION: Sepsis Disrupting the interaction between the immunoglobulin-like cell surface receptor RAGE and the adaptor protein LCP2 could treat sepsis.
BioCentury | Dec 17, 2020
Product Development
Two non-amyloid therapies for Alzheimer’s advance to late-stage trials
Novo’s semaglutide to test metabolic, neuroprotective mechanism; AB Science’s masitinib is testing neuroinflammatory hypothesis
Items per page:
1 - 10 of 90